Given the high frequency of CRLF2 rearrangements and JAK2 point mutations in children and AYAs with DS-ALL [8], we then tested the hypothesis that the sequenced TSLPRCART and ruxolitinib strategy would be efficacious in newly-created preclinical CRLF2 + DS-ALL models. The gene discussed is CRLF2; the disease is acute lymphoblastic leukemia.